Sources of Type I Interferons in Infectious Immunity: Plasmacytoid Dendritic Cells Not Always in the Driver's Seat
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Type I Interferons (IFNs) are hallmark cytokines produced in immune responses to all classes of pathogens. Type I IFNs can influence dendritic cell (DC) activation, maturation, migration, and survival, but also directly enhance NK and T/B cell activity, thus orchestrating various innate and adaptive immune effector functions. Therefore, type I IFNs have long been considered essential in the host defense against virus infections. More recently, it has become clear that depending on the type of virus and the course of infection, production of type I IFNs can also lead to immunopathology or immunosuppression. Similarly, in bacterial infections type I IFN production is often associated with detrimental effects for the host. Although most cells in the body are thought to be able to produce type I IFNs, plasmacytoid DCs (pDCs) have been termed the natural “interferon producing cells” due to their unique molecular adaptations to nucleic acid sensing and ability to produce high amounts of type I IFN. Findings from mouse reporter strains and depletion experiments in in vivo infection models have brought new insights and established that the role of pDCs in type I IFN production in vivo is less important than assumed. Production of type I IFNs, especially the early synthesized IFNβ, is rather realized by a variety of cell types and cannot be mainly attributed to pDCs. Indeed, the cell populations responsible for type I IFN production vary with the type of pathogen, its tissue tropism, and the route of infection. In this review, we summarize recent findings on the cellular source of type I IFNs in different infectious settings, ranging from virus, bacteria, and fungi to eukaryotic parasites. The implications from these findings for the development of new vaccination and therapeutic designs targeting the respectively defined cell types are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780 · cited 4×
“Type I IFN production, however, can also have deleterious roles in chronic viral and bacterial infections, and can lead to immunopathologies such as inflammatory disorders and autoimmunity (1, 2, 10, 11).”
BackgroundInfluentialCGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that activates STING.
Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.-P., Ludwig, J., & Hornung, V. (2013) · Nature · doi:10.1038/nature12306 · Cited by 1,695 · cited 1×
“These sensors include the cyclic GMP-AMP synthase (cGAS)/STING pathway, the RNA polymerase III/RIG-I/MAVS pathway, DNA-dependent activator of IRFs (DAI), IFNγ-inducible protein 16 (IFI16), and the DDX family (47, (51) (52) (53) (54) (55) (56) (57) (58) .”
BackgroundVaure, C., & Liu, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00316 · Cited by 842 · cited 3×
“While TLR3 exclusively signals via the TRIF pathway, TLR4 utilizes MyD88 as well as TRIF signaling routes after recognizing its cognate ligand bacterial lipopolysaccharide (LPS).”
BackgroundBlockade of chronic type I interferon signaling to control persistent LCMV infection
Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G. (2013) · Science · doi:10.1126/science.1235208 · Cited by 709 · cited 1×
“Similar to LCMV, Mycobacteria, or Listeria infections (153, 156, 185), it is thought that early robust production of type I IFN in the first 24 h is essential to induce protective innate and adaptive immunity against Plasmodium, while late production of type I IFN impairs host anti-malaria immune responses by inductio…”
Mayer-Barber, K. D., Andrade, B. B., Barber, D. L., Hieny, S., Feng, C. G., Caspar, P., Oland, S., Gordon, S., & Sher, A. (2011) · Immunity · doi:10.1016/j.immuni.2011.12.002 · Cited by 418
Neurons produce type I interferon during viral encephalitis
Delhaye, S., Paul, S., Blakqori, G., Minet, M., Weber, F., Staeheli, P., & Michiels, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602460103 · Cited by 266
Type I interferons in bacterial infections: A balancing act
Kovarik, P., Castiglia, V., Ivin, M., & Ebner, F. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00652 · Cited by 117
Interfering with immunity: detrimental role of type I IFNs during infection
Stifter, S. A., & Feng, C. G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402794 · Cited by 78
Cited by
Autophagy in inflammation, infection, and immunometabolism
Deretic, V. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.018 · Cited by 862
Metadata
- Authors
- Ali, S., Mann-Nüttel, R., Schulze, A., Richter, L., Alferink, J., & Scheu, S.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-04-12
- Volume
- 10
- Pages
- 778-778
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2939595443
- Cited by
- 172
- References
- 10
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.